Karen Yee

10.7k total citations · 1 hit paper
191 papers, 4.0k citations indexed

About

Karen Yee is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Karen Yee has authored 191 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Hematology, 65 papers in Genetics and 50 papers in Molecular Biology. Recurrent topics in Karen Yee's work include Acute Myeloid Leukemia Research (108 papers), Chronic Myeloid Leukemia Treatments (43 papers) and Acute Lymphoblastic Leukemia research (41 papers). Karen Yee is often cited by papers focused on Acute Myeloid Leukemia Research (108 papers), Chronic Myeloid Leukemia Treatments (43 papers) and Acute Lymphoblastic Leukemia research (41 papers). Karen Yee collaborates with scholars based in Canada, United States and Australia. Karen Yee's co-authors include Andre C. Schuh, Aaron D. Schimmer, Mark D. Minden, Vikas Gupta, Joseph Brandwein, Francis J. Giles, Tracy Murphy, Michael Andreeff, Marina Konopleva and Joseph L. Pater and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Karen Yee

175 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

2016 336 citations Karen Yee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karen Yee Canada	30	2.1k	1.8k	850	739	593	191	4.0k
Martha Arellano United States	27	2.0k 1.0×	2.6k 1.5×	848 1.0×	720 1.0×	870 1.5×	119	4.4k
Dianne Pulte United States	31	1.0k 0.5×	1.4k 0.8×	1.4k 1.7×	569 0.8×	690 1.2×	87	3.5k
Hugo F. Fernández United States	35	1.6k 0.8×	3.6k 2.0×	878 1.0×	755 1.0×	1.1k 1.9×	172	4.9k
Sung‐Soo Yoon South Korea	35	1.6k 0.8×	1.8k 1.0×	1.5k 1.8×	637 0.9×	263 0.4×	342	4.2k
Joseph Brandwein Canada	40	1.8k 0.8×	2.7k 1.5×	1.8k 2.1×	1.0k 1.4×	1.2k 2.0×	191	5.3k
Sikander Ailawadhi United States	28	1.1k 0.5×	1.7k 1.0×	1.4k 1.7×	620 0.8×	287 0.5×	312	3.1k
Martin Höglund Sweden	37	1.5k 0.7×	3.4k 1.9×	1.2k 1.5×	1.6k 2.1×	1.1k 1.9×	134	5.1k
Michael Rytting United States	31	1.1k 0.5×	2.1k 1.2×	1.3k 1.6×	656 0.9×	2.1k 3.5×	96	4.2k
Massimo Breccia Italy	38	1.7k 0.8×	4.1k 2.3×	942 1.1×	2.6k 3.5×	711 1.2×	403	5.6k
B. Douglas Smith United States	43	2.8k 1.4×	4.2k 2.4×	1.3k 1.6×	1.5k 2.1×	947 1.6×	171	6.3k

Countries citing papers authored by Karen Yee

Since Specialization

Citations

This map shows the geographic impact of Karen Yee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Yee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Yee more than expected).

Fields of papers citing papers by Karen Yee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Yee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Yee. The network helps show where Karen Yee may publish in the future.

Co-authorship network of co-authors of Karen Yee

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Yee. A scholar is included among the top collaborators of Karen Yee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Yee. Karen Yee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cortes, Jörge E., Gail J. Roboz, Maria R. Baer, et al.. (2025). Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. Journal of Hematology & Oncology. 18(1). 7–7. 7 indexed citations

Yee, Karen, et al.. (2025). The clinical outcomes, safety profiles, and treatment patterns of electron beam therapy for basal cell carcinoma. 4. 126–128.

Sabloff, Mitchell, et al.. (2024). Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario. Current Oncology. 31(8). 4656–4674. 1 indexed citations

Buckstein, Rena, Jeannie Callum, Anca Prica, et al.. (2024). Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE. Transfusion. 64(2). 223–235. 1 indexed citations

Garcia‐Manero, Guillermo, Karen Yee, Francisca Hernández, et al.. (2024). Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.. Journal of Clinical Oncology. 42(16_suppl). 6509–6509. 1 indexed citations

Flank, Jacqueline, et al.. (2024). Evaluation of voriconazole therapeutic drug monitoring in malignant hematology patients. Journal of Oncology Pharmacy Practice. 31(7). 1094–1103. 1 indexed citations

Wang, Eunice S., Jörge E. Cortes, Justin M. Watts, et al.. (2024). Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib. Blood. 144(Supplement 1). 1514–1514.

Atenafu, Eshetu G., Steven M. Chan, Vikas Gupta, et al.. (2023). Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia. Acta Haematologica. 146(5). 366–372. 1 indexed citations

Buckstein, Rena, Karen Yee, Michelle Geddes, et al.. (2023). The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma. 64(3). 651–661. 3 indexed citations

10.

Assouline, Sarit, Julie Bergeron, Caroline Lambert, et al.. (2023). Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine. Haematologica. 108(11). 2946–2958. 6 indexed citations

11.

Mozessohn, Lee, Ning Liu, Brian Leber, et al.. (2023). Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes. JCO Oncology Practice. 19(4). e559–e569. 3 indexed citations

12.

Lucero, Josephine Anne, et al.. (2023). Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS). Current Oncology. 30(7). 6177–6196. 4 indexed citations

13.

Atenafu, Eshetu G., Taylor Young, Steven M. Chan, et al.. (2022). Safety of re‐challenging adults with acute lymphoblastic leukemia with PEG‐asparaginase‐induced severe hypertriglyceridemia when treated with a pediatric‐inspired regimen. SHILAP Revista de lepidopterología. 4(1). 232–235. 2 indexed citations

14.

Barber, Claire, Diane Lacaille, Peter Faris, et al.. (2020). Evaluating Quality of Care for Rheumatoid Arthritis for the Population of Alberta Using System-level Performance Measures. The Journal of Rheumatology. 48(4). 482–485. 9 indexed citations

15.

Khopkar, Uday, Murlidhar Rajagopalan, Puneet K. Singhal, et al.. (2018). Prevalence and Burden Related to Genital Warts in India. Viral Immunology. 31(5). 346–351. 14 indexed citations

16.

Roboz, Gail J., Hagop M. Kantarjian, Karen Yee, et al.. (2017). Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 124(2). 325–334. 49 indexed citations

17.

Bhaskaran, Abhishek, L.G. Singer, Deepali Kumar, et al.. (2017). Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients. Clinical Microbiology and Infection. 24(6). 640–645. 18 indexed citations

18.

Yee, Karen, David W. Hedley, Sue Chow, et al.. (2016). A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. Investigational New Drugs. 34(5). 614–624. 27 indexed citations

19.

Brandwein, Joseph, Brian Leber, Kang Howson‐Jan, et al.. (2008). A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over. Leukemia. 23(4). 631–634. 10 indexed citations

20.

Yee, Karen, Elias Jabbour, Hagop M. Kantarjian, & Francis J. Giles. (2005). Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Annals of Hematology. 84(S1). 18–24. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact